AKTX (Akari Therapeutics) Volatility: 235.97% (As of Jul. 09, 2026)


AKTX Akari Therapeutics PLC AKTX
32 GF Score
Price $12.94
View Full Analysis

What is Akari Therapeutics Volatility?

Akari Therapeutics AKTX -7.39% 32 Volatility is 235.97% as of Jul. 09, 2026. GuruFocus rates AKTX with a GF Score™ of 32/100.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-07-09), Akari Therapeutics's Volatility is 235.97%.

Akari Therapeutics  (NAS:AKTX) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Akari Therapeutics Volatility Related Terms

AKTX vs MBRX, JAGX, ANEB: Volatility Comparison

For the Biotechnology subindustry, Akari Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akari Therapeutics Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akari Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Akari Therapeutics's Volatility falls into.


AKTX
32GF Score
Akari Therapeutics PLC AKTX
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akari Therapeutics  (NAS:AKTX) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 235.97% mean?
Akari Therapeutics (AKTX) has a Volatility of 235.97% as of Jul. 09, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Akari Therapeutics and its competitors.
Is Akari Therapeutics' Volatility too high?
Akari Therapeutics' current Volatility is 235.97%. Overall, Akari Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' Volatility compare to MBRX and JAGX?
Akari Therapeutics' Volatility of 235.97% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Akari Therapeutics and its competitors. Akari Therapeutics's current Volatility is 235.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (AKTX) has a current Volatility of 235.97%. The current Volatility is 235.97%. Akari Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Akari Therapeutics (AKTX), the current Volatility is 235.97% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akari Therapeutics Business Description

Address 401 East Jackson Street, Suite 3300, Tampa, FL, USA, 33602
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
32GF Score

Get the complete analysis for AKTX

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.94
Price